SA PRO
Free Account
Vera Therapeutics, Inc.VERANASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 92% recommend buying.

Consensus Rating
Buy
13 analysts·Moderate coverage
92%
Rating Distribution
Strong Buy
18%
Buy
1185%
Hold
18%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 72% higher.

Bear Case
$33.00
-27%
Consensus
$77.60
+72%
Bull Case
$97.00
+115%
Price Range13 analysts
Low
Consensus
High
$33.00
$97.00
Current Target
Current Price
$45.04
Upside to Target
$32.56

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Dec 19, 2025Goldman Sachs
Vera Therapeutics price target raised to $95 from $55 at Goldman Sachs
Target:$95.00
+99.2%from $47.69
Dec 11, 2025Wedbush
Vera Therapeutics price target raised to $33 from $23 at Wedbush
Target:$33.00
-27.3%from $45.42
Dec 8, 2025Evercore ISI
Vera Therapeutics price target raised to $97 from $75 at Evercore ISI
Target:$97.00
+111.9%from $45.78
Dec 5, 2025Pivotal Research
Vera Therapeutics (VERA) PT Raised to $73 at TD Cowen
Target:$73.00
+71.3%from $42.61
Nov 28, 2025H.C. Wainwright
H.C. Wainwright Reiterates Buy Rating on Vera Therapeutics (VERA)
Target:$90.00
+170.0%from $33.33
Jun 3, 2025Scotiabank
Vera Therapeutics price target raised to $65 from $55 at Scotiabank
Target:$65.00
+110.3%from $30.91
Mar 21, 2024Wedbush
Vera Therapeutics (VERA) PT Raised to $34 at Wedbush
Target:$34.00
-20.7%from $42.87
Jan 26, 2024Raymond James
Raymond James Upgrades Vera Therapeutics (VERA) to Strong Buy
Target:$37.00
+22.6%from $30.18
Dec 18, 2023Raymond James
Vera Therapeutics' Kidney Disease Drug Has Opportunity In A Competitive Development Landscape: Analyst
Target:$29.00
+83.1%from $15.84
Jan 4, 2023Jefferies
Jefferies Downgrades Vera Therapeutics to Hold, Lowers Price Target to $6
Target:$6.00
-5.8%from $6.37
Jan 4, 2023H.C. Wainwright
HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Lowers Price Target to $15
Target:$15.00
-18.0%from $18.30
Nov 18, 2022J.P. Morgan
JP Morgan Maintains Overweight on Vera Therapeutics, Raises Price Target to $38
Target:$38.00
+115.7%from $17.62
May 2, 2022H.C. Wainwright
HC Wainwright & Co. Initiates Coverage On Vera Therapeutics with Buy Rating, Announces Price Target of $35
Target:$35.00
+75.0%from $20.00

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance